Rite Aid lowers guidance
This article was originally published in The Tan Sheet
Executive Summary
Drug store chain revises fiscal 2005 sales and earnings guidance to reflect slowing Rx sales growth, lower third-party reimbursement rates and the growing impact of mail-order competition. The firm expects sales of approximately $17 bil. with net earnings between $122 mil. and $150 mil., a decrease from the previously forecasted $17.1 bil. to $17.3 bil. with earnings in the $121 mil. to $167 mil. range. Though Rite Aid is "disappointed" with the downward trend, the chain is addressing the issues in the near-term with a TV ad campaign, "an aggressive pharmacy customer acquisition program in key markets and an increased emphasis on prescription file buys," according to CEO Mary Sammons...
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.